No Data
No Data
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)